 |
|
|
| |
Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & -2)
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Eric Lawitz1, Eric M. Yoshida2, Maria Buti3, John M. Vierling4, Piero L. Almasio5, Savino Bruno6, Peter J. Ruane7, Tarek I. Hassanein8, Jacob P. Lalezari9, Beat Mullhaupt10, Brian Pearlman11, 12, Wei Gao13, Hsueh-Cheng Huang13, Aimee Shepherd13, Brynne Tannenbaum13, Doreen Fernsler13, Jerry J. Li13, Anjana Grandhi13, Shuyan Wan13, Frank Dutko13, Wendy W. Yeh13, Rebeca Plank13, Bach-Yen T. Nguyen13 , Janice Wahl13, Eliav Barr13, Joan R. Butterton13
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2University of British Columbia, Vancouver, BC, Canada; 3Hospital Vall D Hebron, Barcelona, Spain; 4Baylor College of Medicine, Advanced Liver Therapies, Houston, TX, USA; 5U. O. di Gastroenterologia, Palermo, Italy; 6IRCCS Istituto Clinico Humanitas and Humanitas University, Rozzano, Italy; 7Ruane Medical and Liver Health Institute, Los Angeles, CA, USA; 8Southern California GI and Liver Centers, Coronado, CA, USA; 9Quest Clinical Research, San Francisco, CA, USA; 10University Hospital Zurich, Zurich, Switzerland; 11Atlanta Medical Center, Atlanta, GA, USA; 12Emory School of Medicine, Atlanta, GA, USA; 13Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
